比卡鲁胺治疗前列腺癌的疗效研究  

Efficacy of bicalutamide in the treatment of prostate cancer

作　　者：许朝阳[1] 钟全发 Xu Zhaoyang;Zhong Quanfa(Department of Pathology,the First People's Hospital of Jiande,Jiande,Zhejiang 311600,China;Department of Urology Surgery,the First People's Hospital of Jiande,Jiande,Zhejiang 311600,China)

机构地区：[1]建德市第一人民医院病理科,浙江省311600 [2]建德市第一人民医院泌尿外科,浙江省311600

出　　处：《中国基层医药》2020年第11期1290-1293,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨比卡鲁胺对前列腺癌的治疗作用。方法选择2014年1月至2019年1月建德市第一人民医院收治的前列腺癌患者95例作为研究对象,95例患者在治疗前采集血液样本为病例组,选择85例体检健康者作为对照组;记录前列腺癌患者在比卡鲁胺治疗前以及治疗后3、6、9、12个月的临床症状变化以及疗效,采集患者治疗后12个月血液样本为治疗组,并且通过反转录聚合酶链式扩增(RT-PCR)法检测比卡鲁胺对前列腺癌患者血清miRNA-125b和miRNA-21表达的影响。结果前列腺癌患者治疗后,前列腺体积和血清前列腺特异性抗原(PSA)表达量明显降低(治疗后3个月与治疗前比较,前列腺体积:t=6.22,P=0.00;PSA:t=5.14,P=0.00;治疗后6个与治疗前比较,前列腺体积:t=8.32,P=0.00;PSA:t=4.11,P=0.00;治疗后12个月与治疗前比较,前列腺体积:t=10.14,P=0.00;PSA:t=9.25,P=0.00;治疗后6个月与治疗后3个月比较,前列腺体积:t=3.82,P=0.00;PSA:t=6.23,P=0.00;有效率比较,χ^2=6.38,P=0.00。治疗后12个月与治疗后3个月比较,前列腺体积:t=4.16,P=0.00;PSA:t=5.77,P=0.00;有效率比较,χ^2=5.74,P=0.00。治疗后12个月与治疗后6个月比较,前列腺体积:t=8.11,P=0.00;PSA:t=4.92,P=0.00;有效率比较,χ^2=4.44,P=0.00);RT-PCR结果显示与对照组相比,病例组miRNA-125b和miRNA-21的表达量明显升高(t=6.22、6.88,P=0.01、0.00),而比卡鲁胺治疗后,前列腺癌患者血清miRNA-125b和miRNA-21的表达明显降低。结论比卡鲁胺可以减轻前列腺癌患者的临床症状,缩小前列腺体积,降低前列腺癌患者血清miRNA-125b和miRNA-21的表达。Objective To explore the therapeutic effect of bicalutamide on prostate cancer.Methods Ninety-five patients with prostate cancer in the First People's Hospital of Jiande were selected from January 2014 to January 2019.All 95 patients received blood samples before treatment were selected as case group,and 85 healthy subjects were selected as control group.The clinical symptoms of the patients before treatment and after treatment with bicalutamide for 3,6,9,12 months were recorded.The blood samples were taken as the treatment group at 12 months after treatment.The effect of bicalutamide on the expression of miRNA-125b and miRNA-21 in serum of patients with prostate cancer was detected by RT-PCR.Results After treatment,the prostate volume and serum prostate specific antigen(PSA)expression were significantly reduced(3 months after treatment compared with before treatment,prostate volume:t=6.22,P=0.00;PSA:t=5.14,P=0.00;6 months after treatment compared with before treatment,prostate volume:t=8.32,P=0.00;PSA:t=4.11,P=0.00;12 months after treatment compared with before treatment,prostate volume:t=10.14,P=0.00;PSA:t=9.25,P=0.00;6 months after treatment compared with 3 months after treatment,prostate volume:t=3.82,P=0.00;PSA:t=6.23,P=0.00;effective rate:χ^2=6.38,P=0.00.One year after treatment compared with 3 months after treatment,prostate volume:t=4.16,P=0.00;PSA:t=5.77,P=0.00;effective rate:χ^2=5.74,P=0.00.One year after treatment compared with 6 months after treatment,the prostate volume:t=8.11,P=0.00;PSA:t=4.92,P=0.00;effective rate:χ^2=4.44,P=0.00).And with the extension of treatment time,the treatment effect was significantly enhanced.RT-PCR results showed that compared with the control group,the expression levels of miRNA-125b and miRNA-21 in the case group were significantly increased(t=6.22,6.88,P=0.01,0.00).After treatment with bicalutamide,the levels of miRNA-125b and miRNA-21 in serum of prostate cancer patients were significantly reduced.Conclusion Bicalutamide can reduce the pain and increase the efficac

关 键 词：前列腺肿瘤 有效率 微RNAS 疼痛 表达 抗原 比卡鲁胺 

分 类 号：R737.25[医药卫生—肿瘤]